Objectives: Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR) are increased in various inflammatory and infectious diseases. We investigated the activation and prognostic value of plasma suPAR (P-suPAR) in patients experiencing their first acute alcohol pancreatitis (AAP).
A cute pancreatitis (AP) is an inflammatory disease with an increasing incidence and wide spectrum of severity and is one of the most common gastrointestinal diseases requiring hospitalization. 1 Gallstones and alcohol are the main etiologies with biliary pancreatitis predominating in most countries. 2, 3 In Finland, alcohol is the leading cause of morbidity accounting for approximately 70% of cases. 4, 5 In AP, premature activation of trypsin causes pancreatic autodigestion and results in a local inflammatory process. The release of cytokines and other inflammatory mediators is characteristic of this process, which results in the recruitment of various immune cells. 6 Urokinase-type plasminogen activator receptor (uPAR) is a membrane protein expressed in cells such as monocytes, neutrophils, activated T-lymphocytes, macrophages, endothelial cells, and cancer cells. [7] [8] [9] Systemic levels of its soluble form (suPAR) are associated with activation of the immune system and inflammatory processes. 9, 10 Systemic levels of suPAR are documented to have prognostic value in sepsis 11 and systemic inflammatory response syndrome 12 as well as in various cancers, including pancreatic ductal adenocarcinoma, 13 gastric cancer, 14 and colorectal cancer. 15 Acute pancreatitis is usually a self-limiting disease that resolves within days, but around 20% of patients develop a more severe disease including local complications and/or organ failure defined in the revised Atlanta classification. 16, 17 Pancreatic necrosis as well as presence of organ failure in AP is associated with significant mortality and, therefore, early risk stratification is of clinical importance. [18] [19] [20] [21] At least 9 scoring systems, 22 aiming to determine the severity of AP on admission, have been described, such as Acute Physiology and Chronic Health Examination (APACHE II), 23 the Ranson criteria, 24 and Modified Glasgow Score. 25 In addition to elaborative scoring systems, attention has also focused on finding an individual laboratory marker to assess the severity of AP, such as hematocrit, 26 C-reactive protein (CRP), 27 creatinine, 28 procalcitonin, 29 and serum urea nitrogen. 30 Despite numerous candidates proposed for predicting the severity of AP, no consensus on criterion has been reached and new approaches are needed. 22 Our aim was to study the activation and prognostic value of plasma suPAR (P-suPAR) in patients experiencing their first acute alcohol pancreatitis (AAP).
MATERIALS AND METHODS
The study population consisted of 120 patients with first AAP. The patients were admitted to Tampere University Hospital between January 2001 and March 2005. In this study, patient recruitment, clinical data collection, and sample collection were conducted prospectively. The patient data used in this study have been studied previously and published in a randomized controlled trial from the same group. 31 From the 120 patients with AAP, blood samples taken during hospitalization were available from 104 patients.
Diagnosis of AAP was based on typical clinical features (epigastric pain, nausea, vomiting) and elevated pancreatic enzymes (amylase at least 3 times over the normal upper limit). Ultrasonography and/or computed tomography were performed to confirm the diagnosis if necessary. Alcohol was determined as the probable etiology by history of heavy drinking, laboratory markers such as carbohydrate-deficient transferrin, mean corpuscular volume, and glutamyltransferase; questionnaires such as Alcohol Use Disorders Identification Test (AUDIT) and Short Alcohol Dependence Data (SADD); and exclusion of other possible etiologies (biliary, autoimmune, trauma, medication, hypertriglyceridemia, hypercalcemia, and hereditary).
Acute pancreatitis was classified according to the revised Atlanta classification into mild (pancreatic inflammation only), moderately severe (transient organ failure that resolves within 48 hours and/or local or systemic complications), and severe (persistent organ failure, >48 hours). 17 For the statistical analysis, moderately severe and severe AAP were combined and are here referred to as non-mild AAP. Samples for P-suPAR determination were taken during hospitalization (median 4 days after admission; from 68 patients on days 1-4) from 104 patients with their first AAP and stored at −70°C. Control samples were obtained from 78 (75%) patients 6 to 24 months after discharge from the hospital. From the control samples, 1 patient with acute appendicitis at the time of the follow-up visit was excluded. Thus, the final control group consisted of 77 patients.
Plasma suPAR concentrations were measured using a commercial enzyme-linked immunosorbent assay from Virogates A/S (Birkerød, Denmark) according to manufacturer's instructions.
Statistical Analysis
Statistical analysis was carried out using IBM SPSS Statistics for Windows (Version 21.0, Armonk, NY). P values under 0.05 were considered statistically significant. Because of the skewness of the data, Kruskal-Wallis (comparison between more than 2 groups) or Mann-Whitney U (comparison between 2 groups) nonparametric tests were used to test for statistical significance. The χ 2 test was used to test for statistical significance between 2 categorical variables, and Wilcoxon signed rank test between related samples, respectively. Value of P-suPAR as an independent marker was evaluated using binomial logistic regression model adjusted for potential confounders. Receiver operating characteristic (ROC) curves as well as sensitivity, specificity, and predictive values were used to determine the prognostic value of suPAR and commonly used laboratory markers (CRP, hematocrit, and creatinine). The optimal cutoff value for P-suPAR in predicting the severity of AAP was determined using the Youden index (highest sum of sensitivity and specificity; sensitivity + specificity − 1). The Kaplan-Meier curve was used to determine the cumulative incidence of complications in AAP and the differences between groups were compared using the log-rank test. The results are presented as medians, ranges, and interquartile ranges (IQRs).
RESULTS
Acute alcohol pancreatitis was considered mild in 69 (66%), moderately severe in 29 (28%), and severe in 6 (6%) patients. For further analysis, moderately severe and severe AAP were combined, and referred to as non-mild AAP (n = 34; 35%). The demographic and clinical characteristics of patients with mild and non-mild AAP are shown in Table 1 . Amount of alcohol consumed before an episode of pancreatitis and the length of hospital stay were associated with the severity of AAP. During the first 4 days after admission, female sex was associated with significantly higher P-suPAR values and smoking suggested a trend for significance as seen in Table 2 . There were no significant differences between P-suPAR values on days 1 to 2 (n = 26) and values on days 3 to 4 (n = 42) in mild (median, 4.2; IQR, 3.0-5.0 vs 4.0; 2.9-4.7 ng/mL, P = 0.43) or non-mild AAP (6.2; 5.5-9.4 vs 5.7; 4.7-6.5 ng/mL, P = 0.46).
Median P-suPAR concentrations were significantly higher in non-mild AAP (6.2 ng/mL, 5.0-7.9) than in mild AAP (4.2 ng/mL, 3.1-5.6; P < 0.001). The significance also remained in a binomial regression analysis adjusted for potential confounders (age, sex, alcohol consumption, AUDIT, SADD, smoking status, and admission laboratory markers; CRP, creatinine, hematocrit) with an OR of 1.2 (95% confidence interval [CI], 1.0-1.5). suPAR was the only variable to reach statistical significance in the multivariate analysis.
The prognostic value of P-suPAR in assessing AAP severity was quantified by determining the area under the curve (AUC) from the ROC curve. When the analysis was made 1 to 4 days after admission (68 patients; mild n = 54; 79%, non-mild n = 14; The AUC values for commonly used predictive laboratory markers were lower than those for P-suPAR (Fig. 1) . An optimal cutoff level for non-mild AAP on admission was estimated from the ROC curve using the Youden index. At a cutoff level of 5.0 ng/mL, sensitivity and specificity to predict a nonmild AAP were 79% and 78%, respectively, as seen in Table 3 . High suPAR values (≥5.0 ng/mL) were also associated with a significantly higher rate of total complications in AAP (Fig. 2) . To identify patients with mild disease a cutoff level with 100% sensitivity was determined from the ROC curve. At a cutoff level of 3.7 ng/mL, 24 of 68 patients received values below cutoff with sensitivity and negative predictive value of 100% (Table 3 ). The suPAR values in non-mild and mild disease analyzed early during an episode (days 1-4) of AAP as well as in recovery are illustrated in Figure 3 .
In a binomial regression analysis adjusted for potential confounders (age, sex, alcohol consumption, AUDIT, SADD, smoking status, and admission laboratory markers; CRP, creatinine, hematocrit), only high P-suPAR (≥5.0 ng/mL) on days 1 to 4 remained as an independent marker for severity in AAP (OR, 21.1; 95% CI, 2.8-160.7).
We analyzed P-suPAR values from 77/104 patients 6 to 24 months after the initial episode of AAP and found that median P-suPAR decreased to low levels after recovery (3.1 ng/mL, 2.7-3.8) compared to those measured during an episode of AAP in the same patients (4.7 ng/mL, 3.6-6.3; P < 0.001).
DISCUSSION
Several scoring systems and single laboratory markers have been proposed to assess the severity of AP on admission, but they remain far from optimal. No studies have so far investigated the role of suPAR in AP. We investigated whether P-suPAR correlates with disease severity and whether it has any value as a prognostic biomarker in AAP. We found that P-suPAR is elevated in AAP and is significantly higher in patients with non-mild disease compared to those with mild AAP. Furthermore, we were able to demonstrate that P-suPAR has prognostic value as an independent marker of severity in terms of distinguishing between mild and non-mild AAP on admission. In addition to predicting non-mild AAP, suPAR could be viewed as a prognostic tool for detecting mild AAP. As a usually self-limiting disease, mild pancreatitis requires mostly fluid resuscitation and pain relief and could therefore be triaged to a different treatment setting than moderately severe or severe disease. Combined with the clinical features, suPAR could help in stratifying these patients with mild disease.
In an earlier study, urinary suPAR levels were found to be elevated in chronic pancreatitis (CP) compared to healthy controls but the prognostic value in CP was not investigated further. 13 As a biomarker, suPAR has been found to have limited diagnostic power as suPAR is a nonspecific marker of inflammation. 32, 33 suPAR has been investigated and found to have potential prognostic value in sepsis, 11 systemic inflammatory response syndrome, 12 liver diseases including alcoholic liver disease, 34 and cancers including ductal adenocarcinoma. 13 Tuomi et al 34 reported that heavy alcohol consumption without diagnosed alcoholic liver disease was associated with higher P-suPAR values than in healthy controls. After an episode of AAP, some of the patients in our study may have developed morphological changes applicable to CP and some may have continued heavy alcohol consumption. These factors are the probable explanations for the slightly higher P-suPAR values reported in our study population after recovery from AAP compared to values reported in healthy controls in other studies. 14, 32, 34 During the first 4 days after admission, female sex and smoking were associated with higher suPAR values in our study. Smoking has previously been reported to increase suPAR values but to the best of our knowledge, no link between FIGURE 1. ROC curves of suPAR, CRP, creatinine, and hematocrit. Creatinine was unavailable from 4 patients from whom hematocrit was unavailable from 2 and CRP from 1 of the same patients (n = 64). A, suPAR, maximum CRP, and maximum creatinine are detected on days 1 to 4 and hematocrit on admission (0). B, suPAR detected on days 1 to 4 and CRP, creatinine, and hematocrit on admission. female sex and higher P-suPAR has been reported. 35 In our study, 81% of the women were smokers compared to 58% in men. Also, the women had more non-mild disease than the men (5/16; 31% in women vs 9/52; 17% in men) but this difference was not statistically significant (P = 0.23). Furthermore, smoking status and sex were statistically insignificant factors in the multivariate analysis in predicting the severity of the disease.
The major limitation of the present study was that samples obtained on days 1 to 4 after admission were used to determine the prognostic value of suPAR in AAP. However, earlier studies have shown that P-suPAR remains stably elevated during the first week in general intensive care unit population and bacteremic patients. 11, 32 To the best of our knowledge, no studies have been conducted specifically on the half-life of suPAR, but in vitro suPAR proved to be very stable and less susceptible to freezing and thawing than other inflammatory markers. 36 In addition, P-suPAR levels did not differ significantly between days 1 to 2 and days 3 to 4 in our study. Severe AP, as classified according to the revised Atlanta classification, 17 is associated with a mortality of 30% or even higher. 21, 37 However, in our study, all patients survived the episode of AAP. Thus, it may be that the patients with the most severe disease were not involved in our study, and the suPAR levels of those patients might have been even higher than those of the patients analyzed within the present study. In addition, as the number of severe AAP cases in our study was low (n = 6), analysis of severe and moderately severe AAP could not be conducted separately.
With a cutoff level of 3.7 ng/mL, P-suPAR was below cutoff in 24 patients with mild AAP with an accuracy of 100%. This means that, in our study, one third of the patients with AAP could potentially be treated in nonspecialized centers or on an outpatient basis. Detecting the patients with a certain mild disease on admission would be beneficial when planning the level of treatment. As AP is one of the most common gastrointestinal diseases requiring hospitalization, identifying these patients could lead to substantially more cost-effective care in pancreatitis. However, this finding should be assessed in a large prospective cohort to eliminate the possibility of chance and with regard to the effect of the interventions.
Several scoring systems and single laboratory markers have been proposed to assess the severity of AP, APACHE II being probably the most validated scoring system with good sensitivity and specificity and used as a reference system in many studies. APACHE II was originally developed for general intensive care unit population and requires multiple parameters, of which some are not relevant in AP, and therefore it might be considered time consuming and cumbersome. Some of the scoring systems, for example, the Ranson criteria, require 48 hours to complete, while the highest incidence of organ failure occurs during the first 24 hours. 38 In sepsis, suPAR was found to improve prognostic accuracy and complement a scoring system when combined with APACHE II. 39 Compared to the prognostic accuracy of other prognostic markers and scoring systems studied by Mounzer et al, 22 suPAR could offer competitive accuracy according to our study. We routinely check for other possible etiologies for AP in our clinic and if necessary exclude these by history, liver chemistry, serum calcium and lipid measurements, and ultrasonography/computed tomography. As suPAR is a nonspecific marker for inflammation, there is nevertheless a possibility of an underlying disease that may elevate suPAR, and therefore suPAR should probably be viewed as a general marker of inflammation as is CRP.
Earlier studies have reported varying results regarding the prognostic values of creatinine and hematocrit in AP, ranging from minor to good prognostic significance. 26, 28, 40, 41 In our study, creatinine and hematocrit were of little prognostic value in discriminating between mild and non-mild AAP, possibly due to the small number of severe pancreatitis cases. C-reactive protein as a single marker of severity in AP has been studied and is probably the most widely used individual laboratory marker in clinical practice. 42 C-reactive protein values rise gradually in the course of AP and the best prognostic value in AP is achieved 24 to 48 hours after admission, due to which the potential for early stratification may be lost. 27 This was also established in our study as the AUC of CRP was rather limited on admission. In our study, the prognostic value of P-suPAR was higher than that of CRP on admission or maximum CRP at 1 to 4 days after admission. Although new strategies in triaging patients with AP are needed, we have demonstrated and non-mild (filled dots) AAP analyzed early during an episode (days 1-4) of pancreatitis and after recovery from the disease. *5.0 and 3.7 ng/mL cutoff levels determined from the ROC curve. FIGURE 2. Kaplan-Meier curve showing the cumulative incidence of complications classified in the revised Atlanta classification in patients with high (≥5.0 ng/mL) and low (<5.0 ng/mL) suPAR values. The differences between the groups were calculated using the log-rank test.
